JPMorgan Upgrades ViroPharma (VPHM) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- L3Harris CEO steps down amid conduct review, shares drop
ViroPharma (VPHM) Undervalued, Competitive Threats Overstated - Analyst
March 27, 2013 11:34 AM EDTWells Fargo today maintained an Outperform rating on ViroPharma (NASDAQ: VPHM) with a price target of $35.00 to $37.00. Analyst Brian Abrahams views the stock as undervalued and thinks competitive threats are overstated.
"We conclude that while there are a few interesting... More
NHS Wales Begins Offering ViroPharma's (VPHM) Cinryze
March 25, 2013 7:20 AM EDTAdults and adolescents in Wales living with hereditary angioedema (HAE) - a rare and life threatening genetic disorder - now have access to ViroPharma's (Nasdaq: VPHM) Cinryze (C1 inhibitor [human]), through NHS Wales, following the approval from the All Wales Medicines Strategy Group (AWMSG).[1] Cinryze is the first and only C1 inhibitor approved in Wales for the... More
